Sabeen Arshad, Aneela Maalik, Wajid Rehman, Yousaf Khan, Hina Sarfraz, Liaqat Rasheed, Mohammed B Hawsawi, Mustafa S Alluhaibi, Majed Alharbi
{"title":"新型1,3,4-恶二唑类脲酶和糖尿病抑制剂的发现:设计、合成、SAR、生物学和分子对接筛选","authors":"Sabeen Arshad, Aneela Maalik, Wajid Rehman, Yousaf Khan, Hina Sarfraz, Liaqat Rasheed, Mohammed B Hawsawi, Mustafa S Alluhaibi, Majed Alharbi","doi":"10.2174/0115734064385863250815045326","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Heterocyclic compounds bearing oxygen and nitrogen atoms are key pharmacophores in modern drug design. Among them, 1,3,4-oxadiazoles are notable for their diverse biological activities, including anti-inflammatory, anticancer, antidiabetic, antibacterial, and enzyme inhibitory effects. This study focuses on the synthesis and evaluation of indazole-based 1,3,4-oxadiazole-benzenesulfonothioate hybrids as potential therapeutic agents.</p><p><strong>Method: </strong>A multistep synthetic route was employed to develop a series of eighteen (18) analogues. The synthetic strategy involved the formation of methyl 5-methyl-1H-indazole-3-carboxylate, conversion to carbohydrazide, cyclization with CS<sub>2</sub>, and final coupling with substituted benzenesulfonyl chlorides to yield the target hybrids (1-18).</p><p><strong>Results: </strong>The urease inhibition potential of scaffolds ranged from IC<sub>50</sub> = 17.88 ± 0.36 to 37.98 ± 0.80 μM as compared to the standard drug thiourea (IC<sub>50</sub> = 29.45 ± 0.76 μM). The exceptional urease and α-glucosidase activity was shown by scaffolds (4, 7, 9, 11) due to the presence of electron- withdrawing groups (-F, NO<sub>2</sub>, and Cl). In comparison, the α-glucosidase inhibition potential shown by all the scaffolds was in the range (IC<sub>50</sub> = 3.19 ± 0.27 - 12.24 ± 1.33 μM). Compound-9 showed promising inhibitory potential against urease, with an IC<sub>50</sub> = 17.90 ± 0.30 μM, and α- glucosidase (IC<sub>50</sub> = 3.19 ± 0.27 μM), both indicating minimum IC<sub>50</sub> values.</p><p><strong>Discussion: </strong>The enhanced activity of compounds bearing electron-withdrawing groups (F, NO2, Cl) supports their role in modulating enzyme inhibition. In silico molecular docking further confirmed strong binding affinities with the active sites of target enzymes, correlating well with the experimental results.</p><p><strong>Conclusion: </strong>The synthesized 1,3,4-oxadiazole derivatives demonstrate promising dual inhibitory activity against urease and α-glucosidase, suggesting their potential as lead compounds in the treatment of gastric infections and diabetes. This study contributes to the ongoing development of multifunctional therapeutic agents with improved efficacy and selectivity.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Discovery of Novel 1,3,4-oxadiazole-based Inhibitors Against Urease and Diabetes: Design, Synthesis, SAR, Biological, and Molecular Docking Screening.\",\"authors\":\"Sabeen Arshad, Aneela Maalik, Wajid Rehman, Yousaf Khan, Hina Sarfraz, Liaqat Rasheed, Mohammed B Hawsawi, Mustafa S Alluhaibi, Majed Alharbi\",\"doi\":\"10.2174/0115734064385863250815045326\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Heterocyclic compounds bearing oxygen and nitrogen atoms are key pharmacophores in modern drug design. Among them, 1,3,4-oxadiazoles are notable for their diverse biological activities, including anti-inflammatory, anticancer, antidiabetic, antibacterial, and enzyme inhibitory effects. This study focuses on the synthesis and evaluation of indazole-based 1,3,4-oxadiazole-benzenesulfonothioate hybrids as potential therapeutic agents.</p><p><strong>Method: </strong>A multistep synthetic route was employed to develop a series of eighteen (18) analogues. The synthetic strategy involved the formation of methyl 5-methyl-1H-indazole-3-carboxylate, conversion to carbohydrazide, cyclization with CS<sub>2</sub>, and final coupling with substituted benzenesulfonyl chlorides to yield the target hybrids (1-18).</p><p><strong>Results: </strong>The urease inhibition potential of scaffolds ranged from IC<sub>50</sub> = 17.88 ± 0.36 to 37.98 ± 0.80 μM as compared to the standard drug thiourea (IC<sub>50</sub> = 29.45 ± 0.76 μM). The exceptional urease and α-glucosidase activity was shown by scaffolds (4, 7, 9, 11) due to the presence of electron- withdrawing groups (-F, NO<sub>2</sub>, and Cl). In comparison, the α-glucosidase inhibition potential shown by all the scaffolds was in the range (IC<sub>50</sub> = 3.19 ± 0.27 - 12.24 ± 1.33 μM). Compound-9 showed promising inhibitory potential against urease, with an IC<sub>50</sub> = 17.90 ± 0.30 μM, and α- glucosidase (IC<sub>50</sub> = 3.19 ± 0.27 μM), both indicating minimum IC<sub>50</sub> values.</p><p><strong>Discussion: </strong>The enhanced activity of compounds bearing electron-withdrawing groups (F, NO2, Cl) supports their role in modulating enzyme inhibition. In silico molecular docking further confirmed strong binding affinities with the active sites of target enzymes, correlating well with the experimental results.</p><p><strong>Conclusion: </strong>The synthesized 1,3,4-oxadiazole derivatives demonstrate promising dual inhibitory activity against urease and α-glucosidase, suggesting their potential as lead compounds in the treatment of gastric infections and diabetes. This study contributes to the ongoing development of multifunctional therapeutic agents with improved efficacy and selectivity.</p>\",\"PeriodicalId\":18382,\"journal\":{\"name\":\"Medicinal Chemistry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115734064385863250815045326\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734064385863250815045326","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Discovery of Novel 1,3,4-oxadiazole-based Inhibitors Against Urease and Diabetes: Design, Synthesis, SAR, Biological, and Molecular Docking Screening.
Introduction: Heterocyclic compounds bearing oxygen and nitrogen atoms are key pharmacophores in modern drug design. Among them, 1,3,4-oxadiazoles are notable for their diverse biological activities, including anti-inflammatory, anticancer, antidiabetic, antibacterial, and enzyme inhibitory effects. This study focuses on the synthesis and evaluation of indazole-based 1,3,4-oxadiazole-benzenesulfonothioate hybrids as potential therapeutic agents.
Method: A multistep synthetic route was employed to develop a series of eighteen (18) analogues. The synthetic strategy involved the formation of methyl 5-methyl-1H-indazole-3-carboxylate, conversion to carbohydrazide, cyclization with CS2, and final coupling with substituted benzenesulfonyl chlorides to yield the target hybrids (1-18).
Results: The urease inhibition potential of scaffolds ranged from IC50 = 17.88 ± 0.36 to 37.98 ± 0.80 μM as compared to the standard drug thiourea (IC50 = 29.45 ± 0.76 μM). The exceptional urease and α-glucosidase activity was shown by scaffolds (4, 7, 9, 11) due to the presence of electron- withdrawing groups (-F, NO2, and Cl). In comparison, the α-glucosidase inhibition potential shown by all the scaffolds was in the range (IC50 = 3.19 ± 0.27 - 12.24 ± 1.33 μM). Compound-9 showed promising inhibitory potential against urease, with an IC50 = 17.90 ± 0.30 μM, and α- glucosidase (IC50 = 3.19 ± 0.27 μM), both indicating minimum IC50 values.
Discussion: The enhanced activity of compounds bearing electron-withdrawing groups (F, NO2, Cl) supports their role in modulating enzyme inhibition. In silico molecular docking further confirmed strong binding affinities with the active sites of target enzymes, correlating well with the experimental results.
Conclusion: The synthesized 1,3,4-oxadiazole derivatives demonstrate promising dual inhibitory activity against urease and α-glucosidase, suggesting their potential as lead compounds in the treatment of gastric infections and diabetes. This study contributes to the ongoing development of multifunctional therapeutic agents with improved efficacy and selectivity.
期刊介绍:
Aims & Scope
Medicinal Chemistry a peer-reviewed journal, aims to cover all the latest outstanding developments in medicinal chemistry and rational drug design. The journal publishes original research, mini-review articles and guest edited thematic issues covering recent research and developments in the field. Articles are published rapidly by taking full advantage of Internet technology for both the submission and peer review of manuscripts. Medicinal Chemistry is an essential journal for all involved in drug design and discovery.